Effect of Unani Medicine Jawarish-e-Anarain in Ghasiyan (Nausea)

Clinical Validation of the Unani Pharmacopoeial formulation Jawarish Anarain for symptomatic Relief in Ghasiyan (Nausea)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/08/015401

Enrollment

240

Registered

2018-08-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G00-G99- Diseases of the nervous system Health Condition 2: R110- Nausea

Interventions

Intervention1: Jawarish-e-Anarain: 7gm orally twice daily with plain water for one week Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group of 18-65 years 2. Ghisyan (Nausea) with or without Qai (vomiting)

Exclusion criteria

Exclusion criteria: 1. Known cases of Acute abdomen. 2. Patients with diseases requiring long term treatment 3. Known cases of severe hepatic, renal or cardiac ailments 4. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms of Ghasiyan (Nausea)Timepoint: one week	—

Secondary

Measure	Time frame
Hematological and biochemical assessments for safetyTimepoint: one week	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026